Over the past thirty-five years, Kevin has dedicated his professional career as a strategic, results-driven change agent transforming complex organizations into streamlined, effective mission-driven operations generating measurable impact on important societal issues.

Kevin was named CEO and president of Alliance for Cancer Gene Therapy in December 2018 and elected to its board of directors in June 2022. As chief executive officer, Kevin’s role is focused on solving the next generation of challenges brought by metastatic cancers while continuing to build organizational alliances and joint ventures to develop life-saving cancer cell and gene therapies.

Prior to joining ACGT, Kevin served as president of the Avon Breast Cancer Crusade and executive director of the Avon Foundation for Women. Through his consulting firm, Honeycutt Partners, he served in a variety of roles helping lead major projects for the American Diabetes Association, the New Venture Fund, the Entertainment Industry Foundation, the United Cancer Front, the San Francisco AIDS Foundation and other leading philanthropic organizations.

Kevin currently serves on the Board of Directors of the Global Cancer Institute and Friends of Mozart. He is a past Board member of the Jonsson Cancer Center Foundation at the University of California, Los Angeles.